publication date: Jun. 21, 2019

In Brief

Cathy Eng named co-leader of GI cancer program at Vanderbilt

Cathy Eng, professor of gastrointestinal medical oncology at MD Anderson Cancer Center, was recruited to Vanderbilt University Medical Center as co-leader of the VICC Gastrointestinal Cancer Research Program.

She will oversee an expansion in the clinical and research activities of the medical oncology gastrointestinal cancer disease group at Vanderbilt, as well as develop programs for adolescent and young adult oncology services.

Eng will co-lead the multi-disciplinary Gastrointestinal Cancer Research Program at VICC with Daniel Beauchamp.

Eng’s work has led to numerous practice-changing outcomes, particularly with regard to the use of immunotherapy in metastatic anal cancer.

She has been at MD Anderson for 17 years, where she has served as the associate director of the Colorectal Center, chair of the Clinical Research Committee, and chair of the Multidisciplinary Colorectal Cancer Tumor Board. She has also served as the section leader for the Rare Cancers Subsection for the MD Anderson HPV Malignancies Moonshot Program.

Eng is serving a second term as NCI Rectal/Anal Cancer Task Force chair. She is the lead contact principal investigator for the NCI National Clinical Trials Network Leading Academic Participating Sites grant for two terms.

She was recently elected to the position of co-chair of the Rectal/Anal Subcommittee for the Southwest Oncology Group and serves on the ECOG-ACRIN Cancer Research Group gastrointestinal committee.

 

Mark Bonnen named chair of radiation oncology at UT Health San Antonio

Mark Bonnen was named chairman of the department of radiation oncology in the Long School of Medicine, effective Sept. 1.

Bonnen joins UT Health San … Continue reading Cathy Eng named co-leader of GI cancer program at Vanderbilt

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.